• Sanofi-Aventis SA, of Paris, priced an offering of $7 billion of notes, consisting of six tranches, pursuant to its shelf registration statement. Sanofi will use net proceeds to fund, in part, the consideration payable for its $21.2 billion acquisition of Cambridge, Mass.-based Genzyme Corp. and related costs. (See BioWorld Today, Feb. 7, 2011.)